I have a few links regarding Anti-TNF and contraindications regarding demyelinating disease antecedent. So far I don't have papers that states that anti-TNF causes MS but more like "hypothesis" or what seems to be a potential aggravating factors kinda thing.
Here is one excerpt I found:
Established and progressive multiple sclerosis (MS) is an absolute contraindication to TNFα antagonist therapy. In patients with severe RA and quiescent MS, the appropriateness of TNFα antagonist therapy should be discussed with the neurologist (evaluation of the risk/benefit ratio). Therefore, patients should be routinely asked about past or present neurological symptoms suggestive of “latent” MS. At the slightest doubt, the advice of a neurologist should be obtained.
When there is a family history of MS, the patient should be informed about the risk and carefully monitored for neurological manifestations.
However, there is no recommendation to perform MRI of the central nervous system in patients who have no clinical manifestations. The detection of white-matter microlesions is a common situation whose interpretation is unclear, and the investigation may therefore generate confusion about the best treatment decision.
Source: Thao Pham and al.(2011), "TNF ALPHA ANTAGONIST THERAPY and safety monitoring", Joint Bone Spinevol.1,p.15-185.
Results:
Four studies on the risk of demyelinating diseases in IBD were identified. One study revealed an observed prevalence of MS at onset of IBD at 3.7 times the expected (95% CI, 0.8–10.8). In the Danish anti-TNFα IBD cohort, 4 out of 651 patients developed demyelinating disorders after anti-TNFα treatment. The SMR for developing MS among Danish IBD patients treated with anti-TNFα was 4.2 (95% CI, 0.1–23.0).
The literature review revealed an up to four-fold increased risk of demyelinating diseases, in particular MS, in IBD patients in general. The risk of developing MS in the anti-TNFα treated Danish cohort did apparently not exceed this risk.
Source: Anderson N.N et
al(2008), "Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study",
Journal of Crohn's and Colitis,p.304-309.
Three safety analyses of large series of IBD patients under IFX revealed one patient with demyelination suggestive of MS, who was reported in detail elsewhere, out of 500 patients with CD treated with IFX at the Mayo Clinic, one patient with verified MS out of 651 IBD patients of the Danish
Crohn Colitis Database treated with IFX (followed for a total of 2009 person-years post-treatment), and 3 cases of confirmed demyelination in IBD patients treated with IFX in Edinburgh covering 620 patient-years of follow-up.
Source:Miesler and al.(2010), "A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease",
Journal of Crohn's and Colitis, vol.4, p.251-256.
There is also a paper that refers to 3 cases of MS/MS-like induced disease by anti-tnf (1-infliximab, 2-humira, 3-Etenarcept). It also stipulate that they can't exclude for sure the possibility that it was "real" MS as the follow-up was too short. Fromont A. et
al(2009),"Inflammatory demyelinating events following treatment with anti-tumor necrosis factor",
Cytokine 45, p.55-57.